This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

February 12, 2026

Company name: Modalis Therapeutics Corporation
Stock exchange listing: Tokyo Stock Exchange
Code number: 4883
URL: https://www.modalistx.com/en/
Representative: Haruhiko Morita

Notice Regarding the Recording of Non-Operating Income (Foreign Exchange Income)

Modalis Therapeutics Corporation (hereafter, "the Company") hereby announces the recording of non-operating income (foreign exchange income) and extraordinary loss for the Fiscal Year Ended December 31, 2025.
.

1. Details of non-operating income (foreign exchange income)

For the Fiscal Year Ended December 31, 2025, the Company recorded foreign exchange income of 10 million yen as non-operating income due to fluctuations in foreign exchanges rates. This was mainly attributed to foreign exchange income arising from revaluation of foreign currency denominated assets and liabilities of the Company.

2. Impact on earnings

Regarding the impact, please refer to "Consolidated Financial Results for the Fiscal Year Ended December 31, 2025" disclosed on February 12, 2026.